Higher advisory panel use likely cause of longer US device decision times
This article was originally published in SRA
Executive Summary
The total time from receipt to decision for original pre-market approvals (PMAs) for medical devices in the US appears to be edging upwards, based on the latest available data. But that may reflect a higher-than-average proportion of advisory committee meetings scheduled for fiscal year 2013 applications rather than review inefficiencies.